Mark Bamforth on his rise to success
02 July 2012
Mark Bamforth, President and CEO of multi-million pound firm Gallus Biopharmaceuticals, has been profiled by leading newspaper Scotland on Sunday, in which he talked about his work in the chemical sector.
Mark Bamforth profiled as a leader in chemicals field by Scotland on Sunday
GlobalScot Mark Bamforth has appeared in Scotland on Sunday in a feature documenting his rise to the top of the chemicals sector in the US.
In the interview, Bamforth talked about the challenges of heading up his own company and his experiences of working in Scotland before he moved to the US. He also paid tribute to Scotland’s dynamic chemicals sector.
Bamforth’s company, Gallus BioPharmaceuticals, has just completed a $20 million expansion of clinical manufacturing, equipment and development facilities at its St. Louis facility. The 8,000 square-foot area was changed from a cafeteria into a manufacturing facility designed to create products that are used to make drugs for clinical trials.
Gallus BioPharmaceuticals is a provider of contract services to biopharmaceutical companies for process development, clinical and commercial manufacturing. Biopharmaceuticals are medical drugs produced using biotechnology and include proteins and nucleic acids used for therapeutic or diagnostic purposes.
Led by President and CEO Mark Bamforth, the St. Louis-based firm has 200 employees. It is owned by Ridgemont Equity Partners.
Mark has also been honoured as the third member of Global Scot’s Hall of Fame by Scottish Enterprise Chief Executive, Lena Wilson. GlobalScot launched its Hall of Fame in late 2011 to honour those members who have made a particularly significant contribution to Scotland over the past decade.
A GlobalScot since 2001, Mark has consistently gone above and beyond in his support of Scottish businesses over the years and is also a founder and trustee of the Saltire Foundation.